Compliance Radar
Who was sanctioned, and for what?
Fines, court rulings and incidents from Europe and North America: 756 cases from 32 jurisdictions, each with an official source and checked against that source before publication. Filter by country, area of law and sector. Click a chart to drill down one level.
Click a bar to drill down one level.
Where?
by regionAll jurisdictions
What for?
by area of lawAll areas of law
Who?
by company- ExxonMobil Chemical Limited 2 cases 8 % · €513,011
- AFCO (Tochtergesellschaft der Zep Inc.) 1 case 4 % · €157,452
- Alkaloids of Australia, Alkaloids Corporation, Boehringer, Linnea, Transo-Pharm (C2 PHARMA Kronzeuge) 1 case 4 % · €13.4m
- Caroline J. Campbell (Beschäftigte der ImmunityBio, Inc.) 1 case 4 % · €288,298
- Colorcon Limited 1 case 4 % · €176,590
- Dompé U.S. Inc. 1 case 4 % · €27.5m
- Estee Lauder Cosmetics Ltd. 1 case 4 % · €463,765
- EyePoint Pharmaceuticals, Inc. 1 case 4 % · €4.08m
- Gilead Sciences, Inc. 1 case 4 % · €177.8m
- Guangxi Kelun Pharmaceutical Co., Ltd. 1 case 4 % ·
- 14 more14 cases
When?
per quarter, by date of decision| Period | Cases | Total |
|---|---|---|
| Q3 2023 | 0 | — |
| Q4 2023 | 0 | — |
| Q1 2024 | 0 | — |
| Q2 2024 | 0 | — |
| Q3 2024 | 0 | — |
| Q4 2024 | 0 | — |
| Q1 2025 | 0 | — |
| Q2 2025 | 0 | — |
| Q3 2025 | 0 | — |
| Q4 2025 | 0 | — |
| Q1 2026 | 0 | — |
| Q2 2026 | 1 | €288,298 |
| Q3 2026 | 0 | — |
1 case
6 Apr 2026 Caroline J. Campbell (Beschäftigte der ImmunityBio, Inc.)ImmunityBio employee sells shares ahead of news of FDA delay €288,298
In May 2023, an employee of the biotech company sold 48,495 shares with knowledge of the non-public information that the FDA would delay approval of the medicine Anktiva; after the announcement, the share price fell by around 55 %. Under the settlement, she is paying 157,066.28 USD in disgorgement, 18,130.97 USD in interest and a civil penalty of 157,066.28 USD.
Trading bans and blackout periods must be known to all employees with access to approval or trial data, not just to the management board.
Insider trading ban for employees, handling of approval information
- Authority / court
- U.S. Securities and Exchange Commission (SEC)
- Area of law
- Capital markets and financial supervision · Market abuse and insider dealing
- Legal basis
- Section 10(b) Securities Exchange Act 1934, Rule 10b-5
- Action
- Fine
- Status of proceedings
- final
- Sector
- Chemicals and pharmaceuticals
Original amount 332,263.53 USD, converted at the ECB reference rate of 2 Apr 2026.
- SEC Files Settled Insider Trading Charges Against California Biotech Employee Decision of an authority
Checked against the official source on 25 Sep 2026 · Direct link